Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion description "[Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion evidence source_evidence_literature NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion SIO_000772 25480824 NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion wasDerivedFrom befree-2016 NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_assertion wasGeneratedBy ECO_0000203 NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.
- befree-2016 importedOn "2016-02-19" NP1245357.RAuiiUVLOw09uvrejE4C8GWuoDlHhAA_Ulxwi_0ymk9xI130_provenance.